ArticleTranslational cancer research2019
Effects of okadaic acid and hematein on human lung adenocarcinoma A549 cells and responses of mitochondria and endoplasmic reticulum apoptosis pathways.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Altering phosphorylation in cancer through PP2A modifiers.Cancer cell international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOkadaic acid (OA) and hematein are both able to inhibit the proliferation of human lung adenocarcinoma A549 cells. However, it is largely unknown about their combined effects on proliferation and apoptosis of A549 cells.
methodsThe combined effects of the two drugs on proliferation of A549 cells and the responses of mitochondria and endoplasmic reticulum (ER) apoptosis pathways were investigated.
resultsMTT assay showed that both OA and hematein significantly inhibited proliferation of A549 cells, and the combined drugs could further increase the inhibition ratio with lower dosages. Inverted phase contrast microscope and scanning electron microscope (SEM) analysis indicated that the combined drugs aggravated the appearance of apoptotic bodies and damaged cells. Compared to the single drug treated groups, reactive oxygen species (ROS) contents were significantly higher in the groups treated by the combined drugs, and mitochondrial membrane potential was significant lower. Western blot indicated that pro-apoptotic Bax that involved in mitochondrial apoptosis pathway increased, the anti-apoptotic protein Bcl-2 decreased, and the ER apoptosis-related proteins CHOP, Calpain2, JNK1 and IRE1 increased.
conclusionsThis work demonstrates that OA combined hematein can more effectively inhibit proliferation of A549 cells, and induce apoptosis of A549 cells via mitochondria and ER dependent pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.